Menu Back toSession-5-Track-A-LNP-Delivery-Approaches-Applications

DIA/FDA Oligonucleotide-Based Therapeutics Conference


Session 5 Track A: Clinical Experience with Lipid Nanoparticle- Based Delivery of Oligonucleotides

Session Chair(s)

Christine  Swenson

Christine Swenson

  • Head, Global Regulatory Affairs
  • Moderna Therapeutics, United States
Delivery of oligonucleotides using lipid nanoparticles (LNP) has been an emerging area of interest over the past decade. Clinical progress with LNP-mediated delivery of siRNAs, mRNAs, and saRNAs will be discussed.
Learning Objective :

At the conclusion of this session, participants should be able to:

  • Understand the use of LNP approaches for delivery of various oligonucleotides
  • Become familiar with clinical efficacy and safety using this modality for different diseases

Speaker(s)

Pushkal  Garg

Development and Approval of ONPATTRO, the First RNAi Therapeutic

Pushkal Garg

  • Alnylam Pharmaceuticals, Inc., United States
Christine  Swenson

Emerging Clinical Data for Intratumor and Systemic Administration of mRNA Therapies

Christine Swenson

  • Head, Global Regulatory Affairs
  • Moderna Therapeutics, United States
Nagy  Habib

MTL-CEBPA, The First Small Activating RNA Therapy in Clinical Development

Nagy Habib

  • Head of Research and Development
  • MiNA Therapeutics Limited , United Kingdom